RT Journal Article
T1 A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study.
A1 Rangel-Zuñiga, Oriol Alberto
A1 Vals-Delgado, Cristina
A1 Alcala-Diaz, Juan Francisco
A1 Quintana-Navarro, Gracia M
A1 Krylova, Yelizaveta
A1 Leon-Acuña, Ana
A1 Luque, Raul Miguel
A1 Gomez-Delgado, Francisco
A1 Delgado-Lista, Javier
A1 Ordovas, Jose Maria
A1 Perez-Martinez, Pablo
A1 Camargo, Antonio
A1 Lopez-Miranda, Jose
K1 MIRN30a microRNA, human
K1 ROC Curve
K1 Diabetes Mellitus, Type 2
K1 Diet, Mediterranean
K1 Linear Models
K1 Area Under Curve
AB MicroRNAs (miRNAs) regulate the expression of genes associated with the development of diseases, including type 2 diabetes mellitus (T2DM). However, the use of miRNAs to predict T2DM remission has been poorly studied. Therefore, we aimed to investigate whether circulating miRNAs could be used to predict the probability of T2DM remission in patients with coronary heart disease. We included the newly diagnosed T2DM (n = 190) of the 1,002 patients from the CORDIOPREV study. Seventy-three patients reverted from T2DM after 5 years of dietary intervention with a low-fat or Mediterranean diet. Plasma levels of 56 miRNAs were measured by OpenArray. Generalized linear model, receiver operating characteristic (ROC), Cox regression, and pathway analyses were performed. ROC analysis based on clinical variables showed an area under the curve (AUC) of 0.66. After a linear regression analysis, seven miRNAs were identified as the most important variables in the group's differentiation. The addition of these miRNAs to clinical variables showed an AUC of 0.79. Cox regression analysis using a T2DM remission score including miRNAs showed that high-score patients have a higher probability of T2DM remission (hazard ratio [HR]low versus high, 4.44). Finally, 26 genes involved in 10 pathways were related to the miRNAs. We have identified miRNAs (hsa-let-7b, hsa-miR-101, hsa-miR-130b-3p, hsa-miR-27a, hsa-miR-30a-5p, hsa-miR-375, and hsa-miR-486) that contribute to the prediction of T2DM remission in patients with coronary heart disease.
PB Cell Press
SN 2162-2531
YR 2020
FD 2020-11-05
LK http://hdl.handle.net/10668/16949
UL http://hdl.handle.net/10668/16949
LA en
NO Rangel-Zuñiga OA, Vals-Delgado C, Alcala-Diaz JF, Quintana-Navarro GM, Krylova Y, Leon-Acuña A, et al. A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study. Mol Ther Nucleic Acids. 2020 Nov 11;23:255-263
NO The CORDIOPREV study is supported by the Fundación PatrimonioComunal Olivarero, Junta de Andalucía (Consejería de Salud, Consejería de Agricultura y Pesca, Consejería de Innovación, Ciencia y Empresa), Diputaciones de Jaén y Córdoba, Centro de Excelencia en Investigación sobre Aceite de Oliva y Salud and Ministerio de Medio Ambiente, Medio Rural y Marino, Gobierno de España; Ministerio de Economía y Competitividad (AGL2012/39615, PIE14/00005, and PIE14/00031 to J.L.-M.; AGL2015-67896-P to J.L.-M. and A.C.); Consejería de Innovación, Ciencia y Empresa, Proyectos de Investigaciónde Excelencia, Junta de Andalucía (CVI-7450 to J.L.-M.); and by theFondo Europeo de Desarrollo Regional (FEDER), JPI HDHL-NutriCog (PCIN-2016-084 to J.L.-M.). The CIBEROBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. O.A.R.-Z. and A.C. are supported by an ISCIII research contract (Programa Miguel-Servet CP19/00142 and CP14/00114, respectively). J.M.O. is supported by the US Department of Agriculture under agreement no. 8050-51000-098-00D
DS RISalud
RD Apr 5, 2025